glp-1 drug manufacturers Costs Explained: Managing Coverage Challenges top glp 1 drug companies
Description
How Will Medicare and Medicaid Coverage Evolve for GLP-1 Drugs in 2025-2026
Unlike GLP-1 agonists that primarily act on the hypothalamus, amylin agonists exert their strongest effects through brainstem area postrema activation and dramatic gastric slowing exceeding that of any other peptide class
But efficacy is only half the story
(popularly called the Gila Monster)
This actually strengthens the failure-to-warn argument
For startups serving this market, those interruptions are not edge cases
